Komori
General Meetings of Shareholders4553TOWA PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice of Convocation of the 70th Annual General Meeting of Shareholders

At the 70th Annual General Meeting of Shareholders, the company will submit proposals concerning the disposition of surplus, the addition of provisions for Class A preferred shares to the Articles of Incorporation, the issuance of Class A preferred shares through a third-party allotment to DBJ (Development Bank of Japan), and the election of directors and directors who are Audit and Supervisory Committee members. The number of directors is expected to increase by 1 to 6, and the number of directors who are Audit and Supervisory Committee members is expected to increase by 1 to 4.

Worth reading
61In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
200
¥100 million (maximum amount to be raised through Class A preferred shares)
Wording
Conditional
How definitive the wording is.

Resolutions for the General Meeting of Shareholders

Annual (70th fiscal year)
2026
Jun 24
Date and time26 days from this disclosure to the meeting
Matters for resolution5 items
  1. Appropriation of surplus

  2. Partial Amendments to the Articles of Incorporation

  3. Issuance of Class A preferred shares through a third-party allotment

  4. Election of 6 directors (excluding directors who are Audit and Supervisory Committee members)

  5. Election of 4 directors who are Audit and Supervisory Committee members

Shareholder Proposal

None (company proposals only)

A shareholder proposal is a resolution submitted by a shareholder, rather than by the company.
Director nomineeThere are 10 candidates (6 directors and 4 directors who are Audit and Supervisory Committee members). There is 1 new candidate and 4 outside directors.
Resolutions for the General Meeting of Shareholders
ItemDetails
Type of shareholders' meetingAnnual (70th fiscal year)
Date and time10:00 a.m., Wednesday, 24 June 2026
Matters for resolutionProposal 1: Appropriation of surplus, Proposal No. 2: Partial Amendments to the Articles of Incorporation, Proposal No. 3: Issuance of Class A preferred shares through a third-party allotment, Proposal No. 4: Election of 6 directors (excluding directors who are Audit and Supervisory Committee members), Proposal No. 5: Election of 4 directors who are Audit and Supervisory Committee members
Shareholder ProposalNone (company proposals only)
Director nomineeThere are 10 candidates (6 directors and 4 directors who are Audit and Supervisory Committee members). There is 1 new candidate and 4 outside directors.
Items this document does not state (1)
Percentage voting in favor

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The funds will be used for growth investments, including the expansion of the company's own manufacturing lines, securing manufacturing capacity, establishing a mutual backup production system, and collaboration. The financing is also intended to strengthen equity capital and stabilize the financial foundation while avoiding dilution of the voting rights of ordinary shares and enabling gradual and flexible fund raising. The increases in the number of directors and directors who are Audit and Supervisory Committee members are intended to strengthen the management and audit systems, respectively.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Convocation of the 70th Annual General Meeting of Shareholders | TOWA PHARMACEUTICAL CO.,LTD. (4553) timely disclosure | Komori